KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Assets Average (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Assets Average for 17 consecutive years, with $5.0 billion as the latest value for Q1 2026.

  • For Q1 2026, Assets Average rose 19.42% year-over-year to $5.0 billion; the TTM value through Mar 2026 reached $5.0 billion, up 19.42%, while the annual FY2025 figure was $4.6 billion, 14.08% up from the prior year.
  • Assets Average hit $5.0 billion in Q1 2026 for Alnylam Pharmaceuticals, up from $4.9 billion in the prior quarter.
  • Across five years, Assets Average topped out at $5.0 billion in Q1 2026 and bottomed at $3.4 billion in Q2 2022.
  • Average Assets Average over 5 years is $4.0 billion, with a median of $3.8 billion recorded in 2023.
  • Year-over-year, Assets Average decreased 1.96% in 2023 and then rose 19.42% in 2026.
  • Alnylam Pharmaceuticals' Assets Average stood at $3.5 billion in 2022, then increased by 8.29% to $3.8 billion in 2023, then grew by 10.12% to $4.2 billion in 2024, then rose by 16.26% to $4.9 billion in 2025, then grew by 2.83% to $5.0 billion in 2026.
  • According to Business Quant data, Assets Average over the past three periods came in at $5.0 billion, $4.9 billion, and $4.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.